[January 10, 2017]

BIO Statement on Proposed Maryland Drug Pricing Legislation

The Biotechnology Innovation Organization today released the following statement regarding proposed drug pricing legislation within the Maryland Senate:

"Any legislative effort to address the affordability of medicines must be patient centered, holistic, and promote patient access to treatments and cures. Biotechnology innovation is not only providing enormous benefits to patients and value to the healthcare system, but it is a proven job creator, employing over 34,000 Marylanders in good, high-paying jobs, with billions invested in the state annually. BIO will oppose legislative proposals that could harm patient access to needed care by undermining competition, disrupting existing drug product availability, or stifling investment in the innovation ecosystem through heavy-handed government intrusion."

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling "innovations transforming our world" and the BIO Newsletter is the organization's bi-weekly email newsletter. Subscribe to the BIO Newsletter.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170110006419/en/

[ Back To TMCnet.com's Homepage ]